N

    Neurosense Therapeutics Ltd (NRSN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.43
    +0.01 (+1.50%)

    Market Cap: $16.11M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    68%(13/19)
    Avg Surprise
    +21.86%
    Streak
    8 Q

    Upcoming Estimates

    Period ending Jun 30, 2026
    EPS Consensus$-0.17
    Range$-0.17 - $-0.17
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$-0.04+76.5%
    60d ago$0.00+100.0%
    30d ago$-0.17+0.0%
    7d ago$-0.17+0.0%
    Current$-0.17
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    Period ending Sep 30, 2026
    EPS Consensus$N/A
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.15---
    Sep 26EST
    		-N/A---
    Jun 26EST
    		-$-0.17---
    Mar 26
    Reported Apr 6
    		$0.00N/A+100.00%Beat+100.0%
    Dec 25
    Reported Mar 25
    		$0.00N/A+100.00%Beat+100.0%
    Sep 25
    Reported Dec 17
    		$-0.04$-0.06+27.27%Beat+63.6%
    Jun 25
    Reported Aug 1
    		$-0.19$-0.23+15.56%Beat-850.0%
    Mar 25
    Reported Apr 7
    		$-0.06N/A+60.00%Beat+82.9%
    Dec 24
    Reported Dec 31
    		$-0.06N/A+60.00%Beat+62.5%
    Sep 24
    Reported Dec 18
    		$-0.11$-0.11+0.00%Beat-210.0%
    Jun 24
    Reported Sep 30
    		$-0.02N/A+88.89%Beat+95.5%
    Mar 24
    Reported Apr 5
    		$-0.35$-0.20-75.00%Miss-6.1%
    Dec 23
    Reported Mar 22
    		$-0.16$-0.20+20.00%Beat+40.7%
    Sep 23
    Reported Nov 28
    		$0.10N/A+138.46%Beat+140.0%
    Jun 23
    Reported Aug 16
    		$-0.44$-0.28-57.14%Miss-41.9%
    Mar 23
    Reported Jun 1
    		$-0.33$-0.29-13.79%Miss-37.5%
    Dec 22
    Reported Mar 22
    		$-0.27$-0.28+3.57%Beat-68.8%
    Sep 22
    Reported Dec 1
    		$-0.25$-0.28+10.71%Beat+0.0%
    Jun 22
    Reported Aug 31
    		$-0.31$-0.28-10.71%Miss-15.0%
    Mar 22
    Reported Apr 14
    		$-0.24$-0.18-33.33%Miss+10.9%
    Dec 21
    Reported Mar 2
    		$-0.16$-0.16+0.00%Beat+19.0%
    Sep 21
    Reported Dec 10
    		$-0.25$-0.21-19.05%Miss-26.6%
    Mar 21
    Reported Jun 30
    		$-0.27$0.00N/AMiss-372.8%
    Dec 20
    Reported Mar 31
    		$-0.27$0.00N/AMiss-372.8%
    Sep 20
    Reported Dec 31
    		$-0.20$0.00N/AMiss-
    Jun 20
    Reported Sep 30
    		$-0.20$0.00N/AMiss-
    Mar 20
    Reported Jun 29
    		$-0.06$0.00N/AMiss-
    Dec 19
    Reported Mar 30
    		$-0.06$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-1.22EV/EBITDA-1.16x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-2175.00%ROIC690.90%
    Financial Health
    Debt/Equity-0.06xInterest Coverage-277.96x
    Current Ratio0.31xQuick Ratio0.31x
    Trading Statistics
    Beta1.60Avg Volume272.60K
    52-Week High$1.9852-Week Low$0.25

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.40
    SMA 20$0.44
    SMA 50$0.58
    SMA 200$0.80
    EMA 10$0.42
    EMA 20$0.45
    EMA 50$0.55
    EMA 200$0.79

    MACD

    Line: -0.05Signal: -0.06Hist: 0.01

    ADX

    ADX: 26.3+DI: 14.8-DI: 23.2

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down68.0
    PSAR$0.50

    Bollinger Bands

    Upper Band$0.55
    Lower Band$0.33
    %B Position4893%(Upper)
    Band Width0.44

    RSI (14-Day)

    Neutral
    41.4

    Momentum Oscillators

    Stoch %K67.1
    Stoch %D61.8
    Williams %R-32.0
    ROC (10d)-1.2%
    Momentum-0.01
    CCI (20d)-22.8
    MFI (14d)29.1

    Volatility Measures

    ATR (14d)$0.06(14.5%)
    StdDev (20d)0.05
    Hist Vol99.3%(High)

    Volume Flow

    VWAP$0.43
    OBV2.9M
    AD Line-12.5M
    CMF (20d)-0.265

    Volume Metrics

    Avg Vol (20d)263.6K
    Vol Ratio0.6x
    VWMA (20d)$0.43

    Pivot Points

    R3$0.47
    R2$0.46
    R1$0.44
    Pivot Point$0.43
    S1$0.41
    S2$0.40
    S3$0.38

    Advanced Oscillators

    TSI-32.89
    Ultimate Osc46.1
    KST-307.67

    Financial Data

    QuarterDec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Total RevenueN/AN/AN/AN/A$0$0$0$0$0$0$0$0
    Cost of RevenueN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
    Gross ProfitN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
    Operating Expenses$3.20M$3.20M$2.35M$2.35M$1.77M$2.11M$3.03M$2.99M$3.29M$2.90M$3.48M$2.99M
    R&D$1.86M$1.86M$1.25M$1.25M$1.09M$1.16M$1.57M$1.88M$1.96M$1.63M$1.91M$1.85M
    SG&A$1.33M$1.33M$1.09M$1.09M$685,000$946,000$1.46M$1.11M$1.33M$1.27M$1.57M$1.14M
    Operating Income$-3,196,500$-3,196,500$-2,346,000$-2,346,000$-1,771,000$-2,107,000$-3,030,000$-2,994,000$-3,287,000$-2,897,000$-3,477,000$-2,991,000
    Interest Income$0$0$0$0$0$0$0$0$3.71M$0$0$62,000
    Interest Expense$11,500$11,500$8,500$8,500$30,000$41,000$2.17M$2.41M$2.20M$12,000$276,000$310,000
    Income Before Tax$-3,208,000$-3,208,000$-2,354,500$-2,354,500$-1,801,000$-2,148,000$-857,000$-5,404,000$-2,950,000$784,000$-5,225,000$-2,924,000
    Income Tax Expense$0$0$0$0$0$0$0$-43,276$0$5.92M$-2,174,000$-62,000
    Net Income$-3,208,000$-3,208,000$-2,354,500$-2,354,500$-1,801,000$-2,148,000$-857,000$-5,404,000$-2,950,000$784,000$-5,225,000$-2,924,000
    EBITDA$-3,192,500$-3,192,500$-2,342,000$-2,342,000N/A$-2,101,750$-851,500$-2,988,750N/A$2.99M$-5,505,500$-2,611,000
    EBIT$-3,196,500$-3,196,500$-2,346,000$-2,346,000$-1,771,000$-2,107,000$-857,000$-2,994,000$-3,287,000$793,000$-5,529,000$-2,614,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about NRSN

    News

    NeuroSense Therapeutics Ltd. Revenue Breakdown – NASDAQ:NRSN

    This article provides an overview of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) financial information on TradingView, focusing on its revenue breakdown. It indicates that the company's financial data, including segments and regional performance, is available through various sources like ICE Data Services, FactSet, and Quartr for SEC filings. The article is primarily a navigation hub to financial details and related tools on the TradingView platform.

    TradingView•8/25/26•
    Neutral

    NeuroSense CEO Details Phase 3 ALS Trial Plans, Canada Filing and Nasdaq Compliance Efforts

    NeuroSense Therapeutics has released a CEO letter detailing plans for its pivotal Phase 3 ALS trial of PrimeC, following FDA clearance. The company is actively pursuing various funding options for the trial and is preparing a New Drug Submission for PrimeC in Canada, targeted for December 2026. Additionally, NeuroSense is addressing Nasdaq listing deficiencies, including a potential reverse share split, while strategic partnership discussions are underway.

    The Globe and Mail•8/15/26•
    Neutral

    Health Canada review path for PrimeC: NeuroSense (NASDAQ: NRSN)

    NeuroSense Therapeutics (NASDAQ: NRSN) has successfully completed the Pre-NDS process with Health Canada for PrimeC, its lead ALS therapeutic candidate. The company aims to file a New Drug Submission (NDS) in December 2026, with Health Canada indicating no concerns with the proposed timeline and alignment on the submission's content and structure. This move is significant given the substantial unmet need for ALS treatments in Canada, where over 3,000 people are currently living with the disease.

    Stock Titan•8/6/26•
    Somewhat-Bullish

    NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada

    NeuroSense Therapeutics announced it has completed the Pre-NDS process with Health Canada for PrimeC, its lead therapeutic candidate for ALS, and is targeting a New Drug Submission (NDS) filing in December 2026. This follows alignment with Health Canada on the submission's content and structure. The company views Canada as a significant market for PrimeC, aiming to bring a promising new treatment to ALS patients, who currently have limited options.

    PR Newswire•8/6/26•
    Bullish

    NeuroSense Therapeutics (NRSN) revises Capital on Demand share sales deal

    NeuroSense Therapeutics has amended its Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC, updating the referenced registration statement to a new Form F-3 (File No. 333-293060), which became effective on July 31, 2026. Under the revised agreement, the company can offer and sell ordinary shares with an aggregate offering price of up to $3,789,822. As of July 31, 2026, NeuroSense had already sold 6,762,825 ordinary shares, generating net proceeds of approximately $6.7 million through the original agreement.

    Stock Titan•8/1/26•
    Neutral

    Frequently Asked Questions About NRSN

    Does NRSN pay dividends?
    Neurosense Therapeutics Ltd (NRSN) does not currently pay a regular dividend.
    What is NRSN's market cap?
    Neurosense Therapeutics Ltd (NRSN) has a market capitalization of $16.11M with a current stock price of $0.43.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In